Edith A. Perez, MD,

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

February 24th 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

January 22nd 2015

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

Dr. Edith Perez on Immune Checkpoint Inhibition in TNBC

December 10th 2014

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

Dr. Perez on a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial

June 20th 2014

Edith A. Perez, MD, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Dr. Edith Perez on T-DM1 and the MARIANNE Trial

December 13th 2013

Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 as a treatment for patients with breast cancer.

Dr. Perez on the Antibody-Drug Conjugate T-DM1

February 13th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Dr. Perez on the Adjuvant Treatment of Breast Cancer

January 28th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, reviews clinical trials that are investigating the optimal adjuvant treatment for patients with breast cancer.

Dr. Perez on the Phase III Eribulin/Capecitabine Study

January 9th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.

Dr. Perez on the Mayo Clinic Breast Cancer Genomic Study

April 23rd 2012

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Dr. Perez on Patient Selection for Adjuvant Chemotherapy

March 28th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses Adjuvant Chemotherapy Patient Selection

Dr. Perez Discusses Optimizing Adjuvant Therapy

February 22nd 2012

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy

Dr. Perez Describes Retesting Recurrent Breast Cancer

February 7th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer

Dr. Perez Discusses Obesity as a Predictive Marker

January 16th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses Obesity as a Predictive Marker

Dr. Perez Discusses the B-34 Clodronate Study

December 22nd 2011

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Florida, Discusses the B-34 Clodronate Study

Dr. Perez Discusses the BOLERO-2 Everolimus Trial

December 14th 2011

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses the BOLERO-2 Everolimus Trial

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

December 8th 2011

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

Dr. Edith Perez Discusses Her Ongoing Research

April 27th 2011

Dr. Edith Perez on Adjuvant Treatments for Breast Cancer

April 15th 2011

Dr. Edith Perez from the Mayo Clinic in Florida on Adjuvant Treatments for Breast Cancer

Dr. Perez on her Anticipated Results for ASCO and SABCS

March 8th 2011